La Lettre du CancérologueLa Lettre du Cancérologue
Trastuzumab par voie sous-cutanée : résultats en néo-adjuvant
ESMO 2012 – D’après Melichar B, abstr. 254PD actualisé
Trastuzumab i.v.(n = 298)
Trastuzumab s.c.(n = 297)
Patients with ≥ 1 adverse event (any grade) 280 (93,9 %) 289 (97,3 %)
Patients with ≥ 1 severe event (grade 3-5) 155 (52,0 %) 154 (51,9 %)
Patients with ≥ 1 serious adverse event 37 (12,4 %) 62 (20,9 %)
Patients with adverse event leading to death 1 (< 1,0 %) 3 (1,0 %)
• The serious adverse event difference was partly attributable to infections ; the remaining serious adverse events were spread across various
categories and 25 events were not easily explicable by the route of delivery or mechanism of action
Tolérance observée dans l'étude HannaH